Literature DB >> 20569057

Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria.

Flavie Pouillot1, Hélène Blois, François Iris.   

Abstract

Natural outbreaks of multidrug-resistant microorganisms can cause widespread devastation, and several can be used or engineered as agents of bioterrorism. From a biosecurity standpoint, the capacity to detect and then efficiently control, within hours, the spread and the potential pathological effects of an emergent outbreak, for which there may be no effective antibiotics or vaccines, become key challenges that must be met. We turned to phage engineering as a potentially highly flexible and effective means to both detect and eradicate threats originating from emergent (uncharacterized) bacterial strains. To this end, we developed technologies allowing us to (1) concurrently modify multiple regions within the coding sequence of a gene while conserving intact the remainder of the gene, (2) reversibly interrupt the lytic cycle of an obligate virulent phage (T4) within its host, (3) carry out efficient insertion, by homologous recombination, of any number of engineered genes into the deactivated genomes of a T4 wild-type phage population, and (4) reactivate the lytic cycle, leading to the production of engineered infective virulent recombinant progeny. This allows the production of very large, genetically engineered lytic phage banks containing, in an E. coli host, a very wide spectrum of variants for any chosen phage-associated function, including phage host-range. Screening of such a bank should allow the rapid isolation of recombinant T4 particles capable of detecting (ie, diagnosing), infecting, and destroying hosts belonging to gram-negative bacterial species far removed from the original E. coli host.

Entities:  

Mesh:

Year:  2010        PMID: 20569057      PMCID: PMC2956564          DOI: 10.1089/bsp.2009.0057

Source DB:  PubMed          Journal:  Biosecur Bioterror        ISSN: 1538-7135


  38 in total

1.  Effect of deleterious mutation-accumulation on the fitness of RNA bacteriophage MS2.

Authors:  M de la Peña; S F Elena; A Moya
Journal:  Evolution       Date:  2000-04       Impact factor: 3.694

Review 2.  Kinetics of phage-mediated biocontrol of bacteria.

Authors:  Stephen T Abedon
Journal:  Foodborne Pathog Dis       Date:  2009-09       Impact factor: 3.171

3.  Viral resistance evolution fully escapes a rationally designed lethal inhibitor.

Authors:  Thomas E Keller; Ian J Molineux; James J Bull
Journal:  Mol Biol Evol       Date:  2009-06-03       Impact factor: 16.240

4.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy.

Authors:  Timothy K Lu; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

5.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products.

Authors:  K A Datsenko; B L Wanner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

6.  ModA and ModB, two ADP-ribosyltransferases encoded by bacteriophage T4: catalytic properties and mutation analysis.

Authors:  Bernd Tiemann; Reinhard Depping; Egle Gineikiene; Laura Kaliniene; Rimas Nivinskas; Wolfgang Rüger
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

7.  Mutagenesis and functional characterization of the RNA and protein components of the toxIN abortive infection and toxin-antitoxin locus of Erwinia.

Authors:  T R Blower; P C Fineran; M J Johnson; I K Toth; D P Humphreys; G P C Salmond
Journal:  J Bacteriol       Date:  2009-07-24       Impact factor: 3.490

8.  Application of lambda Red recombination system to Vibrio cholerae genetics: simple methods for inactivation and modification of chromosomal genes.

Authors:  Shouji Yamamoto; Hidemasa Izumiya; Masatomo Morita; Eiji Arakawa; Haruo Watanabe
Journal:  Gene       Date:  2009-03-05       Impact factor: 3.688

Review 9.  Preventing biofilms of clinically relevant organisms using bacteriophage.

Authors:  Rodney M Donlan
Journal:  Trends Microbiol       Date:  2009-01-21       Impact factor: 17.079

10.  High adsorption rate is detrimental to bacteriophage fitness in a biofilm-like environment.

Authors:  Romain Gallet; Yongping Shao; Ing-Nang Wang
Journal:  BMC Evol Biol       Date:  2009-10-05       Impact factor: 3.260

View more
  17 in total

Review 1.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

2.  Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing.

Authors:  Hiroki Ando; Sebastien Lemire; Diana P Pires; Timothy K Lu
Journal:  Cell Syst       Date:  2015-09-23       Impact factor: 10.304

3.  Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis.

Authors:  Kevin Yehl; Sébastien Lemire; Andrew C Yang; Hiroki Ando; Mark Mimee; Marcelo Der Torossian Torres; Cesar de la Fuente-Nunez; Timothy K Lu
Journal:  Cell       Date:  2019-10-03       Impact factor: 41.582

Review 4.  A new mechanistic approach for the treatment of chronic neuropathic pain with nitrous oxide integrated from a systems biology narrative review.

Authors:  Baptiste Bessiere; François Iris; Aude Milet; Athanasios Beopoulos; Catherine Billoet; Géraldine Farjot
Journal:  Med Gas Res       Date:  2021 Jan-Mar

5.  Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii.

Authors:  Lucia Blasco; Anton Ambroa; Maria Lopez; Laura Fernandez-Garcia; Ines Bleriot; Rocio Trastoy; Jose Ramos-Vivas; Tom Coenye; Felipe Fernandez-Cuenca; Jordi Vila; Luis Martinez-Martinez; Jesus Rodriguez-Baño; Alvaro Pascual; Jose Miguel Cisneros; Jeronimo Pachon; German Bou; Maria Tomas
Journal:  Microorganisms       Date:  2019-11-12

6.  Promises and Pitfalls of In Vivo Evolution to Improve Phage Therapy.

Authors:  James J Bull; Bruce R Levin; Ian J Molineux
Journal:  Viruses       Date:  2019-11-21       Impact factor: 5.048

7.  Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1.

Authors:  Alex Betts; Marie Vasse; Oliver Kaltz; Michael E Hochberg
Journal:  Evol Appl       Date:  2013-07-15       Impact factor: 5.183

Review 8.  Phage therapy: eco-physiological pharmacology.

Authors:  Stephen T Abedon
Journal:  Scientifica (Cairo)       Date:  2014-05-20

9.  Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.

Authors:  Wilbert Sybesma; Christine Rohde; Pavol Bardy; Jean-Paul Pirnay; Ian Cooper; Jonathan Caplin; Nina Chanishvili; Aidan Coffey; Daniel De Vos; Amber Hartman Scholz; Shawna McCallin; Hilke Marie Püschner; Roman Pantucek; Rustam Aminov; Jiří Doškař; D İpek Kurtbӧke
Journal:  Antibiotics (Basel)       Date:  2018-04-23

Review 10.  Engineered bacteriophages as programmable biocontrol agents.

Authors:  Phil Huss; Srivatsan Raman
Journal:  Curr Opin Biotechnol       Date:  2019-12-17       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.